Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Vera Therapeutics ( (VERA) ).
On May 14, 2025, Vera Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made. Stockholders elected three Class I Directors, ratified KPMG LLP as the independent registered public accounting firm, approved executive compensation, and voted for annual advisory votes on executive compensation.
The most recent analyst rating on (VERA) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Vera Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for serious immunological diseases.
Average Trading Volume: 1,005,592
Technical Sentiment Signal: Sell
Current Market Cap: $1.36B
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.